Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review
Oxcarbazepine is often utilized off-label for bipolar and depressive disorders in outpatient settings despite limited evidence. We performed a retrospective chart review on 38 adult outpatients diagnosed with bipolar and depressive disorders (ICD-10 codes F30-39), treated with oxcarbazepine by psych...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Psychiatry Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772598724000175 |
| _version_ | 1831868846891335680 |
|---|---|
| author | Brandon Brown Brian Tong Luke Pro Suzanna Kitten |
| author_facet | Brandon Brown Brian Tong Luke Pro Suzanna Kitten |
| author_sort | Brandon Brown |
| collection | DOAJ |
| description | Oxcarbazepine is often utilized off-label for bipolar and depressive disorders in outpatient settings despite limited evidence. We performed a retrospective chart review on 38 adult outpatients diagnosed with bipolar and depressive disorders (ICD-10 codes F30-39), treated with oxcarbazepine by psychiatrists and psychiatric nurse practitioners between 2015 and 2021. Primary outcomes were Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores, assigned retrospectively from clinical documentation. Patients were predominantly female (70%), aged 20–76 (mean 36), with a mean of 1.8 DSM diagnoses (range 1–4) and 1.7 (range 0–5) concurrent psychotropic medications. A starting mean oxcarbazepine dose of 489 mg/day, titrated to a mean final dose of 663 mg/day, was associated with a CGI-I of 2.5 [2.25, 2.75] and a pre-to-post treatment decrease in CGI-S from 3.4 to 2.4. Overall response and remission rates were 52% and 29%, respectively. Limitations of this study include potential sample bias, documentation bias and rater bias among other limitations inherent to retrospective study designs. |
| first_indexed | 2024-04-24T10:56:34Z |
| format | Article |
| id | doaj.art-a260f073251e46c7821f20a09230be6f |
| institution | Directory Open Access Journal |
| issn | 2772-5987 |
| language | English |
| last_indexed | 2025-03-21T19:01:02Z |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Psychiatry Research Communications |
| spelling | doaj.art-a260f073251e46c7821f20a09230be6f2024-06-05T04:41:58ZengElsevierPsychiatry Research Communications2772-59872024-06-0142100171Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart reviewBrandon Brown0Brian Tong1Luke Pro2Suzanna Kitten3Psychiatry, Carle Health 1802 S. Mattis Ave, Champaign, IL, 61821, USA; Carle Illinois College of Medicine, 506 S Mathews Ave, Urbana, IL, 61801, USA; Corresponding author. Psychiatry, Carle Health 1802 S. Mattis Ave, Champaign, IL, 61821, USA.Psychiatry, Carle Health 1802 S. Mattis Ave, Champaign, IL, 61821, USA; Carle Illinois College of Medicine, 506 S Mathews Ave, Urbana, IL, 61801, USAPsychiatry, Carle Health 1802 S. Mattis Ave, Champaign, IL, 61821, USA; Carle Illinois College of Medicine, 506 S Mathews Ave, Urbana, IL, 61801, USAPsychiatry, Carle Health 1802 S. Mattis Ave, Champaign, IL, 61821, USA; Carle Illinois College of Medicine, 506 S Mathews Ave, Urbana, IL, 61801, USAOxcarbazepine is often utilized off-label for bipolar and depressive disorders in outpatient settings despite limited evidence. We performed a retrospective chart review on 38 adult outpatients diagnosed with bipolar and depressive disorders (ICD-10 codes F30-39), treated with oxcarbazepine by psychiatrists and psychiatric nurse practitioners between 2015 and 2021. Primary outcomes were Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores, assigned retrospectively from clinical documentation. Patients were predominantly female (70%), aged 20–76 (mean 36), with a mean of 1.8 DSM diagnoses (range 1–4) and 1.7 (range 0–5) concurrent psychotropic medications. A starting mean oxcarbazepine dose of 489 mg/day, titrated to a mean final dose of 663 mg/day, was associated with a CGI-I of 2.5 [2.25, 2.75] and a pre-to-post treatment decrease in CGI-S from 3.4 to 2.4. Overall response and remission rates were 52% and 29%, respectively. Limitations of this study include potential sample bias, documentation bias and rater bias among other limitations inherent to retrospective study designs.http://www.sciencedirect.com/science/article/pii/S2772598724000175Major depressive disorderBipolar disorderMood disorderMood stabilizerOxcarbazepineDepressive disorder |
| spellingShingle | Brandon Brown Brian Tong Luke Pro Suzanna Kitten Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review Psychiatry Research Communications Major depressive disorder Bipolar disorder Mood disorder Mood stabilizer Oxcarbazepine Depressive disorder |
| title | Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review |
| title_full | Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review |
| title_fullStr | Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review |
| title_full_unstemmed | Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review |
| title_short | Oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting: A retrospective chart review |
| title_sort | oxcarbazepine for the treatment of bipolar and depressive disorders in the outpatient setting a retrospective chart review |
| topic | Major depressive disorder Bipolar disorder Mood disorder Mood stabilizer Oxcarbazepine Depressive disorder |
| url | http://www.sciencedirect.com/science/article/pii/S2772598724000175 |
| work_keys_str_mv | AT brandonbrown oxcarbazepineforthetreatmentofbipolaranddepressivedisordersintheoutpatientsettingaretrospectivechartreview AT briantong oxcarbazepineforthetreatmentofbipolaranddepressivedisordersintheoutpatientsettingaretrospectivechartreview AT lukepro oxcarbazepineforthetreatmentofbipolaranddepressivedisordersintheoutpatientsettingaretrospectivechartreview AT suzannakitten oxcarbazepineforthetreatmentofbipolaranddepressivedisordersintheoutpatientsettingaretrospectivechartreview |